Publications by authors named "Johanna Rauch"
Eur Respir J
January 2025
Article Synopsis
- Bronchiectasis is caused by high levels of neutrophil serine protease (NSP) activity, and inhibiting Cathepsin C (CatC) may help decrease lung damage caused by neutrophils.
- A Phase II trial tested a new CatC inhibitor (BI 1291583) in 322 adults with bronchiectasis, comparing different doses (1, 2.5, 5 mg) to a placebo over 24 to 48 weeks.
- Results showed that higher doses of BI 1291583 significantly delayed the onset of pulmonary exacerbations, with the 2.5 mg dose being the most effective, while the safety profile was comparable to that of the placebo. *
